Clinical Trials Logo

Bipolar I Depression clinical trials

View clinical trials related to Bipolar I Depression.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02046369 Completed - Clinical trials for Bipolar I Depression

Lurasidone Pediatric Bipolar Study

Illuminate
Start date: March 2014
Phase: Phase 3
Study type: Interventional

A study to evaluate efficacy and safety of flexibly dosed Lurasidone in children and adolescents with bipolar I depression

NCT ID: NCT01403662 Completed - Bipolar Disorder Clinical Trials

Evaluating the Efficacy of Adjunctive Minocycline for the Treatment of Bipolar Depression

Start date: July 2011
Phase: Phase 3
Study type: Interventional

Long-term studies have emphasized that depressive symptoms and episodes account for majority of the illness burden experienced by individuals with bipolar disorder (BD). Previous studies have shown that blood levels of proteins called pro-inflammatory cytokines are abnormal in individuals with bipolar depression. The investigators hypothesize that preventing the production or release of pro-inflammatory cytokines will result in improvement of depressive symptoms in individuals with bipolar depression. Minocycline is a medication that inhibits the activation of immune cells (i.e. microglia) in the brain and reduces the production of pro-inflammatory cytokines. Treatment with minocycline has been shown to have antidepressant-like effects in animal studies and improve symptoms of individuals with schizophrenia. In this study, minocycline (100 mg twice a day) will be administered for 8 weeks to determine if it is an efficacious antidepressant for individuals with bipolar depression.

NCT ID: NCT00812058 Completed - Clinical trials for Bipolar I Depression

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test a new drug, RG2417, to see how the drug affects symptoms of bipolar I depression and to make sure it is safe in humans.

NCT ID: NCT00481195 Completed - Clinical trials for Bipolar I Depression

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Start date: June 2007
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to determine if armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy for adults who are experiencing a major depressive episode associated with Bipolar I Disorder and who are inadequately responsive to their current treatment for a current major depressive episode.